The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation.
暂无分享,去创建一个
[1] Jennifer E. Podesta,et al. Chapter 17 - Engineering cationic liposome siRNA complexes for in vitro and in vivo delivery. , 2009, Methods in enzymology.
[2] I. M. Neiman,et al. [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.
[3] Justine R. Smith,et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 , 2008, Nature.
[4] Y. Rojanasakul,et al. Oxygen Radical-Mediated Pulmonary Toxicity Induced by Some Cationic Liposomes , 2000, Pharmaceutical Research.
[5] Kathryn A. Whitehead,et al. Lipid-like materials for low-dose, in vivo gene silencing , 2010, Proceedings of the National Academy of Sciences.
[6] A. Lee,et al. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[7] B. Strukelj,et al. Potential hepatoprotective effects of fullerenol C60(OH)24 in doxorubicin-induced hepatotoxicity in rats with mammary carcinomas. , 2008, Biomaterials.
[8] Judy Lieberman,et al. Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.
[9] A. Fire,et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.
[10] A. Chaudhuri,et al. Common co‐lipids, in synergy, impart high gene transfer properties to transfection‐incompetent cationic lipids , 2005, FEBS letters.
[11] David F. Williams. On the nature of biomaterials. , 2009, Biomaterials.
[12] G. Gregoriadis,et al. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. , 1980, The Biochemical journal.
[13] L. Zitvogel,et al. The immunogenicity of tumor cell death , 2009, Current opinion in oncology.
[14] W. Shi,et al. Antitumor and antimetastatic activities of vesicular stomatitis virus matrix protein in a murine model of breast cancer , 2009, Journal of Molecular Medicine.
[15] L. Zitvogel,et al. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. , 2008, Cancer research.
[16] K. Braeckmans,et al. The role of nanoparticle concentration-dependent induction of cellular stress in the internalization of non-toxic cationic magnetoliposomes. , 2009, Biomaterials.
[17] L. Cekaite,et al. Suppression of immunostimulatory siRNA-driven innate immune activation by 2'-modified RNAs. , 2007, Biochemical and biophysical research communications.
[18] J. Ruysschaert,et al. Formation and intracellular trafficking of lipoplexes and polyplexes. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[19] Marina A Dobrovolskaia,et al. Nanoparticles and the immune system. , 2010, Endocrinology.
[20] D. Peer,et al. RNAi nanoparticles in the service of personalized medicine. , 2009, Nanomedicine.
[21] D. Peer,et al. RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[22] S. Doak,et al. NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. , 2009, Biomaterials.
[23] Pieter van Dokkum,et al. The nature of , 2006 .
[24] D. Peer,et al. Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target , 2008, Science.
[25] D. Peer,et al. Systemic siRNA delivery to leukocyte-implicated diseases , 2009, Cell cycle.
[26] Samuel I. Miller,et al. LPS, TLR4 and infectious disease diversity , 2005, Nature Reviews Microbiology.
[27] P. Miossec. IL-17 and Th17 cells in human inflammatory diseases. , 2009, Microbes and infection.
[28] A. Hot,et al. IL-17 inhibits human Th1 differentiation through IL-12R beta 2 downregulation. , 2009, Cytokine.
[29] T. Whiteside,et al. TLR4 signaling induced by lipopolysacharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer , 2009, Oncogene.
[30] A. Vella,et al. Understanding how lipopolysaccharide impacts CD4 T-cell immunity. , 2008, Critical reviews in immunology.
[31] Y. Aramaki,et al. Lipoxygenase may be involved in cationic liposome-induced macrophage apoptosis. , 2001, Biochemical and biophysical research communications.
[32] Michael S. Goldberg,et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[33] K. G. Rajeev,et al. Rational design of cationic lipids for siRNA delivery , 2010, Nature Biotechnology.
[34] H. Park,et al. Cutting Edge: Direct Interaction of TLR4 with NAD(P)H Oxidase 4 Isozyme Is Essential for Lipopolysaccharide-Induced Production of Reactive Oxygen Species and Activation of NF-κB1 , 2004, The Journal of Immunology.
[35] Masafumi Nakamura,et al. Lipopolysaccharide (LPS) increases the invasive ability of pancreatic cancer cells through the TLR4/MyD88 signaling pathway , 2009, Journal of surgical oncology.
[36] Jiyan Liu,et al. Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34→Ala mutant , 2008, Journal of experimental & clinical cancer research : CR.
[37] T. Tuschl,et al. RNA interference is mediated by 21- and 22-nucleotide RNAs. , 2001, Genes & development.
[38] Soo-Ho Choi,et al. Macrophages Generate Reactive Oxygen Species in Response to Minimally Oxidized Low-Density Lipoprotein: Toll-Like Receptor 4– and Spleen Tyrosine Kinase–Dependent Activation of NADPH Oxidase 2 , 2009, Circulation research.
[39] A. Judge,et al. Overcoming the innate immune response to small interfering RNA. , 2008, Human gene therapy.
[40] A. Judge,et al. siRNA and innate immunity. , 2009, Oligonucleotides.
[41] L. Coussens,et al. Cancer: An inflammatory link , 2004, Nature.
[42] J. Gatot,et al. DiC14‐amidine cationic liposomes stimulate myeloid dendritic cells through Toll‐like receptor 4 , 2008, European journal of immunology.
[43] V. Torchilin,et al. Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy. , 2009, Molecular pharmaceutics.
[44] H. Rosenberg,et al. Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2–MyD88 signal pathway in dendritic cells and enhances Th2 immune responses , 2008, The Journal of experimental medicine.
[45] D. Peer,et al. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. , 2004, Neoplasia.
[46] L. Coussens,et al. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. , 2005, Cancer cell.
[47] Miklós Tóth,et al. Animal Models of Complement-Mediated Hypersensitivity Reactions to Liposomes and Other Lipid-Based Nanoparticles , 2007, Journal of liposome research.
[48] A. Legat,et al. DiC14-amidine confers new anti-inflammatory properties to phospholipids , 2008, Cellular and Molecular Life Sciences.
[49] Chulhee Choi,et al. Role of NADPH oxidase 4 in lipopolysaccharide-induced proinflammatory responses by human aortic endothelial cells. , 2006, Cardiovascular research.
[50] Marion Jurk,et al. Sequences derived from self-RNA containing certain natural modifications act as suppressors of RNA-mediated inflammatory immune responses. , 2009, International immunology.
[51] A. Sood,et al. Nanomedicine based approaches for the delivery of siRNA in cancer , 2010, Journal of internal medicine.
[52] P. Miossec. Diseases that may benefit from manipulating the Th17 pathway , 2009, European journal of immunology.
[53] Matthias John,et al. RNAi-mediated gene silencing in non-human primates , 2006, Nature.